Quantcast
Last updated on April 16, 2014 at 6:49 EDT

Latest Debiopharm Stories

2014-04-08 04:22:04

- Debio 0932 demonstrated anti-tumor activity and synergy with various SOC agents in in vitro and xenograft models of NSCLC and RCC - LAUSANNE, Switzerland and LEXINGTON, Mass., April 8, 2014 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, and Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription...

2014-04-02 04:21:07

LAUSANNE, Switzerland and HAMBURG, Germany, April 2, 2014 /PRNewswire/ -- - Innovative partnership based on Evotec's Target X projects - Evotec and Debiopharm to share discovery and development efforts Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today a research collaboration and licensing deal with Debiopharm Group(TM), Lausanne, Switzerland. The objective of this collaboration is to identify and...

2014-03-06 04:23:27

LAUSANNE, Switzerland, March 6, 2014 /PRNewswire/ -- Debiopharm Group(TM)(Debiopharm), a Swiss-based global biopharmaceutical group of companies active in drug development, GMP manufacturing of proprietary drugs, diagnostics, and investments, has announced its decision to expand and optimize activities at Debiopharm Research & Manufacturing S.A., its industrial development and production facility in Martigny (Valais, Switzerland), through acquisition of industrial...

2014-02-28 04:21:53

LAUSANNE, Switzerland, February 28, 2014 /PRNewswire/ -- Unilabs, a leading supplier of clinical laboratory and medical diagnostic imaging services in Europe and Diagnoplex SA, a developer of molecular diagnostics for colorectal cancer announced today the Swiss market launch of Colox(R), a non-invasive screening test for colorectal cancer. Colox(R) is offered as a service by Unilabs' clinical diagnostic service laboratories in Switzerland. Additional countries within Unilabs'...

2014-01-08 04:21:06

LAUSANNE, Switzerland, January 8, 2014 /PRNewswire/ -- Spinomix SA, a Swiss company advancing molecular diagnostic through innovative sample preparation technologies and Debiopharm Group(TM)(Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs including oncology as well as companion diagnostics, today announced the successful achievement of a second development milestone on Spinomix' two proprietary...

2013-10-24 12:26:35

GENEVA and LAUSANNE, Switzerland, October 24, 2013 /PRNewswire/ -- Atheris Laboratories, a world leading company in venom-based drug discovery and lead optimization, and Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs including oncology along with companion diagnostics, today announced the signature of a collaboration agreement regarding the Atheris "Reverse-Discovery"(TM) lead...

2013-10-22 08:33:17

Designed to target advanced metastatic renal cell carcinoma, the study will determine the maximum tolerated dose of Debio 0932 in combination with everolimus LAUSANNE, Switzerland and LEXINGTON, Massachusetts, October 22, 2013 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, and Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a...

2013-10-07 04:21:07

SINGAPORE and LAUSANNE, Switzerland, October 7, 2013 /PRNewswire/ -- The Agency for Science, Technology and Research (A*STAR)'s Experimental Therapeutics Centre (ETC), a center of excellence to advance and accelerate drug discovery in Singapore, and Debiopharm Group(TM) (Debiopharm), the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs including oncology as well as companion diagnostics, today...

2013-10-04 04:20:26

LAUSANNE, Switzerland, October 4, 2013 /PRNewswire/ -- Debiopharm Group(TM) (Debiopharm), the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs including oncology and companion diagnostics, will be presenting the 'JCA-Mauvernay Award' on October 5, to Doctors Issay Kitabayashi from Tokyo National Cancer Center Research Institute for his basic research on 'Molecular study of acute myeloid leukemia...

2013-09-23 12:25:42

ALBANY, New York, September 23, 2013 /PRNewswire/ -- New Report Added in ResearchMoz Reports Database Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapies ResearchMoz announces that it has published a new study Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted...